NCT03147612View on ClinicalTrials.gov

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 8, 2018

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia With BCR-ABL1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

Blinatumomab

Given via central catheter

DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given intrathecally or IV

BIOLOGICAL

Filgrastim

Given SC

DRUG

Methotrexate

Given intrathecally or IV

BIOLOGICAL

Pegfilgrastim

Given SC

DRUG

Ponatinib

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER